Immuneering (IMRX) Free Cash Flow (2020 - 2026)
Immuneering (IMRX) posted quarterly Free Cash Flow of -$18.5 million for Q1 2026, down 31.4% year-over-year from -$27.0 million in Q1 2025, and down 85.79% quarter-over-quarter from -$10.0 million in Q4 2025.
Immuneering (IMRX) Free Cash Flow (2020 - 2026) Analysis & Trends
Immuneering's Free Cash Flow history runs 7 years deep, the most recent figure standing at -$18.5 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 31.4% year-over-year to -$18.5 million; the TTM figure through Mar 2026 stood at -$49.9 million (up 6.96% YoY), while the FY2025 annual figure was -$45.5 million, up 17.42% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$18.5 million, down from -$10.0 million in the prior quarter.
- The five-year high for Free Cash Flow was -$9.4 million in Q2 2025, with the low at -$18.5 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$12.0 million (2025), against an average of -$12.5 million.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow tumbled 101.35% in 2022, then jumped 31.37% in 2025.
- Immuneering's Free Cash Flow stood at -$11.8 million in 2022, then retreated by 1.08% to -$11.9 million in 2023, then dropped by 21.54% to -$14.5 million in 2024, then surged by 31.37% to -$10.0 million in 2025, then slumped by 85.79% to -$18.5 million in 2026.
- Business Quant data shows IMRX's Free Cash Flow at -$18.5 million in Q1 2026, -$10.0 million in Q4 2025, and -$12.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | -16.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.53 Mn |
| Jun 30, 2026 | -16.53 Mn |
| Mar 31, 2026 | -18.51 Mn |
| Mar 31, 2026 | -18.51 Mn |
| Dec 31, 2025 | -9.96 Mn |
| Dec 31, 2025 | -9.96 Mn |
| Sep 30, 2025 | -11.98 Mn |
| Sep 30, 2025 | -11.98 Mn |
| Jun 30, 2025 | -9.45 Mn |
| Jun 30, 2025 | -9.45 Mn |
| Mar 31, 2025 | -14.09 Mn |
| Mar 31, 2025 | -14.09 Mn |
| Dec 31, 2024 | -14.52 Mn |
| Dec 31, 2024 | -14.52 Mn |
| Sep 30, 2024 | -13.48 Mn |
| Sep 30, 2024 | -13.48 Mn |
| Jun 30, 2024 | -11.56 Mn |
| Jun 30, 2024 | -11.56 Mn |
| Mar 31, 2024 | -15.53 Mn |
| Mar 31, 2024 | -15.53 Mn |